Image: StatnewsPharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and more
• An FDA advisory panel has recommended the use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected the drug twice previously. • Rising oil prices driven by the conflict with Iran have sparked industry concerns regarding the vulnerability of essential medicine supply chains to price volatility. • These developments highlight critical regulatory shifts for oncology treatments and the impact of geopolitical instability on pharmaceutical costs.
statnews.com



